Table 1 Patient characteristics and laboratory measurements
n (%) or median [IQR] | |
|---|---|
Patient characteristics | |
Age (years) | 53 [37, 63] |
Gender: male/female | 14 (70)/6 (30) |
Weight (kg) | 79 [64, 85] |
Height (m) | 1.69 [1.65, 1.80] |
28-day mortality | 9 (45) |
SAPS II | 78 [69, 90] |
Norepinephrine n (%), and dosage (mg/h) at start | 17 (85), 0.90 [0.60, 1.60] |
Norepinephrine n (%), and dosage (mg/h) after 12 h | 12 (60), 0.65 [0.50, 1.20] |
Vasopressin n (%), and dosage (IE/h) at start | 7 (35) 2.0 [1.5, 2.5] |
Vasopressin n (%), and dosage (IE/h) after 12 h | 5 (25) 2.0 [0.5, 2.0] |
Laboratory parameters before initiation of Cytosorb® | |
Total bilirubin (mg/dl) | 14.7 [11.6, 18.6] |
Conjugated bilirubin (mg/dl) | 12.5 [10.0, 15.1] |
Total BAs (µmol/l) | 59 [44, 140] |
Alanine aminotransferase (U/l) | 160 [96, 271] |
Aspartate aminotransferase (U/l) | 180 [115, 677] |
γ-Glutamyltransferase (U/l) | 446 [96, 941] |
Alkaline phosphatase (U/l) | 368 [160, 780] |